The phase 3 study FIGHT-302 (NCT03656536) is ongoing to evaluate the efficacy and safety of pemigatinib vs. gemcitabine plus cisplatin in the first-line treatment of patients with metastatic CCA with FGFR2 rearrangements [133]. Here, FGFR2 is linked to cholangiocarcinoma.